Efprox-CV Tablet2018-11-13T14:41:59+00:00
efprox-cv-soltech-product

Cefpodoxime   –    200 mg

Clavulanic acid   –   125 mg

1 Aluminium Strip of 6 tablets in mono cartoon

Efprox-CV provides the combination of Cefpodoxime and Clavulanic acid. This combination is effective against many infections. The presence of clavulanic acid is highly essential as this combination prevents the hydrolysis of cefpodoxime in presence of beta lactamase releasing micro-organisms which causes the increase in effectiveness and spectrum of cefpodoxime.

  • Pseudomembranous colitis
  • Serious renal toxicity
  • Anaphylactic shock
  • Skin rashes
  • Abdominal pain
  • Diarrhoea
  • Nephritis
  • Nausea and vomiting
  • Respiratory tract inections

Cefpodoxime is active against both gram positive and gram negative bacteria. It is steady in presence of beta-lactamase enzyme. It causes inhibition of cell wall synthesis and restraining the final step of transpeptidation of peptidoglycon synthesis in cell wall. Inhibition of cell wall synthesis occurs as cefpodoxime binds to PBPs 3. Clavulanic acid protects the cefpodoxime from hydrolysis in presence of beta lactamase and increases the effectiveness and spectrum. It enhances the anti-bacterial activity by enzyme inhibition.

Absorption

Cefpodoxime is absorbed from GIT and gets converted to its active metabolite. The absorption of the drug is more when administered with food.

Clavulanic acid also well absorbed when administered with food than the fasted subjects.

Distribution

Cefpodoxime is well distributed in the body with plasma protein binding about 22-33%. The half life of cefpodoxime is about 2hrs.

The half life of clavulanic acid is about 1hr and it is well distributed into the body. About 25% of the drug is bound to serum.

Excretion

Cefpodoxime excreted in urine in unchanged form in about 12hrs.

About 25-40% of clavulanic acid is excreted in unchanged form in urine in about 6hrs of administration.

  • Patients with allergy to penicillin or other beta lactum
  • Renal impairment
  • Safely administered in pediatric patients
  • Teratogenic to the pregnant patients
  • Develops toxicity
  • Patients with renal impairment
  • Over use causes over growth of non-susceptible organism Concurrent treatment with diuretics